Recent studies have demonstrated that amylin levels are reduced in AD patients [33] and pramlintide, an amylin analogue recently approved for the treatment of diabetes, is known to exert neuroprotective effects in experimental models of AD [74,75]. This evidence concerns the gene IAPP and diabetes mellitus.